In pricing its new amyotrophic lateral sclerosis drug Relyvrio, Amylyx Pharmaceuticals chose a sum that’s just below the current cost of the last ALS drug to win FDA approval. But a drug price watchdog group argues that prices should be set based on therapeutic value, not according to the price of existing medications.
